Prof. Piotr Trzonkowski has set and shown a new path in the fight against autoimmune diseases. His studies on TREGS (T-regulatory) cells are a chance to create an innovative therapy that will be used to treatment early forms of type 1 diabetes.
2023-05-25
Prof. Piotr Trzonkowski, CEO of PolTREG has been awarded the Wprost Health Visioner 2023 Award
See other news
2025-01-09
PolTREG obtains Japanese patent for intrathecal PTG-007 therapy in multiple sclerosis
2024-11-14
PolTREG received a new patent from China for anti-gen specific Tregs cellular therapy
2024-09-26
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
2024-09-16
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
2024-09-09
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence